Literature DB >> 25220687

Dementia and severity of parkinsonism determines the handicap of patients in late-stage Parkinson's disease: the Barcelona-Lisbon cohort.

M Coelho1, M J Marti, C Sampaio, J J Ferreira, F Valldeoriola, M M Rosa, E Tolosa.   

Abstract

BACKGROUND AND
PURPOSE: Handicap has not been explored as a patient-centred outcome measure in Parkinson's disease (PD). The clinical features and medication use in late stages of PD (LS-PD) were reported previously.
METHODS: Handicap, medical conditions, use of healthcare resources and the impact of LS-PD upon caregivers were characterized in a cross-sectional study of LS-PD stages 4 or 5 of Hoehn and Yahr (H&Y). Handicap was measured using the London Handicap Scale (LHS: 0, maximal handicap; 1, no handicap).
RESULTS: The mean LHS score in 50 patients was 0.33 (SD ±0.15). The presence of dementia, the Unified Parkinson's Disease Rating Scale part I score and the H&Y stage in 'off' independently predicted the LHS score (adjusted R(2) = 0.62; P = 0.000). Comorbidities and past medical conditions were frequent. Thirty-five patients lived at their house. Forty-five received unpaid care. Mean visits to the family doctor in the preceding 6 months were 2.2 (SD ±3.0) and to a neurologist 1.7 (SD ±1.0). Use of other health resources was low. Unpaid caregivers spent much time with patients and reported a high burden.
CONCLUSION: Handicap could be measured in LS-PD and the LHS was easily completed by patients and caregivers. The high handicap in our cohort was mostly driven by the presence of dementia, behavioural complaints and the severity of non-dopaminergic motor features. Patients visited doctors infrequently and made low use of health resources, whilst unpaid caregivers reported a high burden.
© 2014 EAN.

Entities:  

Keywords:  Parkinson's disease; advanced; caregiver; dementia; disability; handicap; late stage; quality of life

Mesh:

Year:  2014        PMID: 25220687     DOI: 10.1111/ene.12567

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  12 in total

1.  Disease stage dependency of motor and non-motor fluctuations in Parkinson's disease.

Authors:  Alexander Storch; Kristina Rosqvist; Georg Ebersbach; Per Odin
Journal:  J Neural Transm (Vienna)       Date:  2019-06-19       Impact factor: 3.575

2.  Thalamic Dorsomedial Nucleus Free Water Correlates with Cognitive Decline in Parkinson's Disease.

Authors:  Thomas Guttuso; Daniel Sirica; Duygu Tosun; Robert Zivadinov; Ofer Pasternak; Daniel Weintraub; Francesca Baglio; Niels Bergsland
Journal:  Mov Disord       Date:  2021-12-22       Impact factor: 10.338

3.  Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study.

Authors:  Anette Schrag; Uzma Faisal Siddiqui; Zacharias Anastasiou; Daniel Weintraub; Jonathan M Schott
Journal:  Lancet Neurol       Date:  2016-11-18       Impact factor: 44.182

4.  The Prevalence and Determinants of Neuropsychiatric Symptoms in Late-Stage Parkinsonism.

Authors:  Adrianus L A J Hommel; Marjan J Meinders; Stefan Lorenzl; Richard Dodel; Miguel Coelho; Joaquim J Ferreira; Brice Laurens; Umberto Spampinato; Wassilios Meissner; Kristina Rosqvist; Jonathan Timpka; Per Odin; Michael Wittenberg; Bas R Bloem PhD; Raymond T Koopmans; Anette Schrag
Journal:  Mov Disord Clin Pract       Date:  2020-05-21

5.  Profile of cognitive impairment in late-stage Parkinson's disease.

Authors:  Catarina Severiano E Sousa; Margherita Fabbri; Catarina Godinho; Rita Moiron Simões; Inês Chendo; Miguel Coelho; Isabel Pavão Martins; Joaquim J Ferreira
Journal:  Brain Behav       Date:  2022-03-07       Impact factor: 3.405

6.  Consensus on the Definition of Advanced Parkinson's Disease: A Neurologists-Based Delphi Study (CEPA Study).

Authors:  Maria-Rosario Luquin; Jaime Kulisevsky; Pablo Martinez-Martin; Pablo Mir; Eduardo S Tolosa
Journal:  Parkinsons Dis       Date:  2017-01-23

7.  Validation of a simple screening tool for early diagnosis of advanced Parkinson's disease in daily practice: the CDEPA questionnaire.

Authors:  Pablo Martinez-Martin; Jaime Kulisevsky; Pablo Mir; Eduardo Tolosa; Pilar García-Delgado; María-Rosario Luquin
Journal:  NPJ Parkinsons Dis       Date:  2018-07-02

8.  Safety and preliminary efficacy of intranasal insulin for cognitive impairment in Parkinson disease and multiple system atrophy: A double-blinded placebo-controlled pilot study.

Authors:  Peter Novak; Daniela Arantxa Pimentel Maldonado; Vera Novak
Journal:  PLoS One       Date:  2019-04-25       Impact factor: 3.240

9.  Caregiver burden and health-related quality of life in idiopathic dystonia patients under botulinum toxin treatment: a cross-sectional study.

Authors:  S C Drexel; M Klietz; F Wegner; D Dressler; K Kollewe; L Paracka; A Kutschenko; B Kopp; F Lange
Journal:  J Neural Transm (Vienna)       Date:  2019-12-04       Impact factor: 3.575

Review 10.  Challenges and Perspectives in the Management of Late-Stage Parkinson's Disease.

Authors:  Margherita Fabbri; Linda Azevedo Kauppila; Joaquim J Ferreira; Olivier Rascol
Journal:  J Parkinsons Dis       Date:  2020       Impact factor: 5.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.